Skip to main content
Equibles

Idan Elmelech

CFO

BridgeBio Oncology Therapeutics, Inc. (BBOT)

COO

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Equibles does not estimate personal net worth.

Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get BBOT alerts

About Idan Elmelech

Idan Elmelech is recorded as CFO at BridgeBio Oncology Therapeutics, Inc. (BBOT) since April 21, 2026 and COO at BridgeBio Oncology Therapeutics, Inc. (BBOT) since April 20, 2026. The newest filing on record that lists Idan Elmelech as COO at BridgeBio Oncology Therapeutics, Inc. (BBOT) is dated April 28, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 23, 2026 that Idan Elmelech was appointed principal financial officer, effective April 21, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 23, 2026 that Idan Elmelech was appointed Chief Operating Officer, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member) and 7 others.

“Effective April 21, 2026, the Company’s Board of Directors appointed Mr. Elmelech as the Company’s principal financial officer and Marc Cobo, the Company’s Vice President of Finance and Controller, as the Company’s principal accounting officer.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed April 23, 2026 · Read the filing
“On April 20, 2026, the Board also appointed Idan Elmelech as Chief Operating Officer of the Company, effective immediately.”
BridgeBio Oncology Therapeutics, Inc. Form 8-K, filed April 23, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at BridgeBio Oncology Therapeutics, Inc.

Recent activity